N@N

Targacept Scientists to Present Data Supporting the Potential of NNR Therapeutics for the Treatment of Nervous System Diseases

^{Published on 2010-11-08 11:05:24 - Market Wire}
 

WINSTON-SALEM, N.C.--([ BUSINESS WIRE ])--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that its scientists are scheduled to make several presentations at the 40^th annual meeting of the Society for Neuroscience being held in San Diego, California from November 13 through November 17, 2010.

The presentations are:

• An alpha7 neuronal nicotinic receptor-selective compound enhances neurogenesis and mitigates inflammatory responses in brain following LPS stimulation or exposure to high levels of ionizing radiation, a poster presentation scheduled for Saturday, November 13 at 2:00 p.m. (PST);
• Comparisons of binding affinities for neuronal nicotinic receptors and achbps and structural features for a high affinity, non-selective NNR ligand-achbp co-crystal structure, a poster presentation scheduled for Saturday, November 13 at 4:00 p.m. (PST);
• Characterization of nicotine-induced desensitization of native human alpha7, alpha3beta4 and alpha4beta2 neuronal nicotinic receptors using fast aliquid bulleta application of NNR agonists, a poster presentation scheduled for Saturday, November 13 at 4:00 p.m. (PST);
• Effects of the alpha7 nicotinic agonist TC-7020 on striatal dopamine release correlate with changes in prepulse inhibition in an FGF/dopamine mouse developmental model of schizophrenia, a poster presentation scheduled for Sunday, November 14 at 10:00 a.m. (PST);
• Correlation of analgesic effects mediated by neuronal nicotinic acetylcholine receptor agonists with desensitization of a4b2 receptors, a poster presentation scheduled for Sunday, November 14 at 2:00 p.m. (PST); and
• Targeting novel integrative nuclear FGFR1 signaling (INFS) reconstitutes active neurogenesis in adult brain, a poster presentation scheduled for Monday, November 15 at 3:00 p.m. (PST).

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics(TM) for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is in Phase 3 development as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad(TM) to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. For more information, please visit [ www.targacept.com ].

TARGACEPT

Building Health, Restoring Independencea"

About the Society for Neuroscience

The Society for Neuroscience(SfN) is a nonprofit membership organization of scientists and physicians who study the brain and nervous system. Since its inception in1969, the Societyhasgrown from 500 members to over 40,000. Today, SfNis the world's largest organization of scientists and physicians devoted to advancing understanding of the brain and nervous system.

Forward-Looking Statements

This press release includes aforward-looking statementsa made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements other than statements of historical fact regarding, without limitation: presentations by Targacept scientists at the 40^th annual meeting of the Society for Neuroscience; the medical benefits of NNR Therapeutics; or Targacepta™s plans and expectations. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various important factors, including without limitation the conduct and results of clinical trials and non-clinical studies and assessments of Targacept product candidates; Targacepta™s ability to protect its intellectual property; and the timing and success of submission, acceptance and approval of regulatory filings. These and other risks and uncertainties are described in greater detail under the heading aRisk Factorsa in Targacepta™s most recent Annual Report on Form 10-K and in other filings that it makes with the Securities and Exchange Commission. As a result of the risks and uncertainties, the results or events indicated by the forward-looking statements may not occur. Targacept cautions you not to place undue reliance on any forward-looking statement.

In addition, any forward-looking statement in this press release represents Targacepta™s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Targacept disclaims any obligation to update any forward-looking statement, except as required by applicable law.